Available Until 5/9/2023

ACCP/ASHP BCOP On-Demand Series: A Review of Oral Hypomethylating Agents in MDS and AML (Cert # L229132)

ACPE Numbers: 0217-9999-22-032-H01-P
Pre-Sale Date: 04/13/2022
Content Release Date: 05/18/2022
Expiration Dates: 05/09/2023
CE Credits: 1.5 (ACPE and BPS)
Activity Fee: $110 (ASHP member); $160 (non-member) 

Activity Overview

This webinar series is part of the professional development program for the recertification of the Board Certified Oncology Pharmacist.

This course is intended for BCOPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. 

This online activity is approved for 1.5 hours of continuing pharmacy education credit and/or recertification credit.

This webinar recording covers the use of oral hypomethylating agents in case-based examples, decitabine/cedazuridine use for MDS, oral azacitidine use in AML patients, dosing, and administration for those agents, and related ongoing or upcoming clinical trials.

The American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP) are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The target audience for this webinar is the pharmacist interested in learning more about updated information regarding oncologic management and/or treatment, and for Board-certified Oncology Pharmacists (BCOPs) looking to earn recertification credit.

Board certified pharmacists are eligible to receive up to 1.5 hours of recertification credit for completing this webinar. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment. 

This webinar is not intended for those preparing to take the BPS Oncology Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/onc-review. 

These activities are part of the ACCP and ASHP professional development program for BCOP recertification approved by the BPS. 

For full program information, please visit: http://elearning.ashp.org/catalog/onc-recert

Learning Activity

ACPE Number

Contact Hours (ACPE and BPS)

Assessment Pass Point

ACCP/ASHP BCOP On-Demand Series: A Review of Oral Hypomethylating Agents in MDS and AML

0217-9999-22-032-H01-P

1.5

76%

After participating in this CPE activity, learners should be able to:

  • Review the mechanism of action and compare the pharmacokinetic profiles of oral hypomethylating agents to their parenteral counterparts.
  • Analyze results of key trials for decitabine/cedazuridine in myelodysplastic syndrome (MDS) and oral azacitidine in acute myeloid leukemia (AML).
  • Assess the place in therapy of oral hypomethylating agents for MDS and AML based on current approvals and guideline recommendations.
  • Design a patient-specific plan for dosing, administration, monitoring, and supportive care for each agent.

Danielle Schlafer, Pharm.D., BCOP
Clinical Pharmacy Specialist, Leukemia
Emory Healthcare/Winship Cancer Institute
Atlanta, GA

Melanie Brooke Bernhardt, Pharm.D., M.S., BCOP, BCPPS
Assistant Professor, Baylor College of Medicine
Director of Pharmacy, Texas Children’s Global HOPE
Houston, TX 

Christopher T. Elder, Pharm.D., BCOP
Clinical Oncology Pharmacist, Florida Cancer Specialists and Research Institute
Fort Myers, FL

Ryan Beechinor, Pharm.D., BCPS, BCOP
Carrie Berry, Pharm.D., BCPS, BCOP
Janet Bramell, Pharm.D., BCPS, BCOP
Nicholas Chow, Pharm.D., BCOP
Crystal Coff, Pharm.D., BCOP
Muoi Gi, Pharm.D., BCOP
Brittney  Hale, Pharm.D., BCOP
Elisabeth Hebert, B.Pharm, M.Sc, BCOP
Anna Jan, Pharm.D., BCOP
Abby  Kim, PharmD, BCOP
Beatrix Lam, Pharm.D. BCPS, BCOP
Lesli  Lavery, Pharm.D., BCOP, CPP
Michael Leung, Pharm.D., BCOP
Valerie Lindeborg, Pharm. D., BCOP, BCSCP
Robert Luschen, Pharm.D., BCOP
Mary  Miao, Pharm.D., BCOP
Donald Moore, Pharm.D., BCPS, BCOP, DPLA
Nancy  Nix, Pharm.D., BCPS, BCOP
Jeanne Noe, Pharm.D., BCOP
Jason  Oller, Pharm.D., BCOP
Maria Pidoubny, Pharm.D., BCOP
Saima Qasim, M.Pharm,  BCOP, BCSCP
Mike  Reed, RPh, BCOP, BCCCP, BCPS
Sean Reilly, RPh, BS Pharm, Pharm.D., BCOP
Kristen Rychalsky, Pharm.D., BCPS, BCOP
Hope Schenk, Pharm.D., BCOP
Lindsay Stansfield, Pharm.D., BCPS, BCOP
Rachel Vaught, Pharm.D., BCOP
Catherine Wallace, Pharm.D., BCOP
Chen Xu, Ph.D., M.S., BCOP
Barbara Yim, Pharm.D., BCOP

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ACCP and ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speaker’s bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP and required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identify and resolve conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Dr. Danielle Schlafer: Consultant – Cardinal Health, CTI BioPharma; Individual stock – Arrowhead Pharmaceuticals
  • Dr. Melanie Brooke Bernhardt: Consultant – Jazz; Advisory Board – BTG International, Mesoblast, Servier; Research – Bristol Myers Squibb, BTG International, Celgene
  • Dr. Christopher T. Elder: Advisory Board – Acceleron, AstraZeneca, Bristol Myers Squibb, Glaxo Smith Kline, Kyowa Kirin, Pharmacosmos, Pfizer 

All other planners, presenters, reviewers, ASHP and ACCP, and others with an opportunity to control content report no financial relationships relevant to this activity.

This activity consists of audio and slides, a PDF book chapter, an attestation statement, and an activity evaluation. Learners must review all content and complete the attestation statement and evaluation to receive continuing pharmacy education credit for the activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ACCP and ASHP.